Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1730 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-01-01

Study Completion Date

2025-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Bismuth-containing quadruple therapy was recommended as a first-line treatment for Helicobacter pylori infection. This study aimed to compare real-world outcomes of various bismuth-containging quadruple regimens and identify factors influencing treatment failure. A multicenter retrospective analysis was conducted and study outcomes included eradication rates and incidence of adverse events.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Bismuth-containing Quadruple Therapy for Helicobacter Pylori First-line Treatment of Different Tetracycline Doses

NCT05431075

Helicobacter Pylori Infection

COMPLETED PHASE4

Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days

NCT04901117

Helicobacter Pylori Infection

UNKNOWN PHASE4

P-CABs-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication

NCT07285096

Helicobacter Pylori Infection

RECRUITING

Efficacy of 7-day Versus 14-day Bismuth Quadruple Therapy for the Eradication of Helicobacter Pylori（SHARE2302)

NCT05997433

Helicobacter Pylori Infection

RECRUITING NA

Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Therapy of Different Tetracycline Doses and Frequencies.

NCT05432115

Helicobacter Pylori Infection

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Helicobacter Pylori Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

vonoprazan-based quadruple therapies

This study is a retrospective study, and all data have been collected in advance with no active intervention required.

Intervention Type OTHER

This study is a retrospective study, and all data have been collected in advance with no active intervention required.

tegoprazan-based quadruple therapies

This study is a retrospective study, and all data have been collected in advance with no active intervention required.

Intervention Type OTHER

This study is a retrospective study, and all data have been collected in advance with no active intervention required.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

This study is a retrospective study, and all data have been collected in advance with no active intervention required.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients aged 18-70 years, regardless of gender;
* absent history of receiving H. pylori eradication therapy;
* diagnosed with H. pylori infection through at least one of the following methods: rapid urease test, ¹³C/¹⁴C-urea breath test, or histopathological examination.

Exclusion Criteria

* patients with incomplete medical records, including missing treatment details, absence of post-treatment follow-up test results, or failure to complete essential follow-up assessments;
* patients who received treatment regimens that did not comply with the quadruple regimens specified in this study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No